EHAB vs. AHCO, AVAH, CHE, OPCH, AMED, BTSG, ADUS, GLPG, FUSN, and LMAT
Should you be buying Enhabit stock or one of its competitors? The main competitors of Enhabit include AdaptHealth (AHCO), Aveanna Healthcare (AVAH), Chemed (CHE), Option Care Health (OPCH), Amedisys (AMED), BrightSpring Health Services (BTSG), Addus HomeCare (ADUS), Galapagos (GLPG), Fusion Pharmaceuticals (FUSN), and LeMaitre Vascular (LMAT). These companies are all part of the "medical" sector.
AdaptHealth (NASDAQ:AHCO) and Enhabit (NYSE:EHAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.
AdaptHealth received 74 more outperform votes than Enhabit when rated by MarketBeat users. Likewise, 59.23% of users gave AdaptHealth an outperform vote while only 12.00% of users gave Enhabit an outperform vote.
AdaptHealth presently has a consensus price target of $12.42, indicating a potential upside of 30.98%. Enhabit has a consensus price target of $10.13, indicating a potential upside of 10.17%. Given Enhabit's stronger consensus rating and higher possible upside, equities analysts plainly believe AdaptHealth is more favorable than Enhabit.
Enhabit has lower revenue, but higher earnings than AdaptHealth. Enhabit is trading at a lower price-to-earnings ratio than AdaptHealth, indicating that it is currently the more affordable of the two stocks.
In the previous week, AdaptHealth had 9 more articles in the media than Enhabit. MarketBeat recorded 11 mentions for AdaptHealth and 2 mentions for Enhabit. AdaptHealth's average media sentiment score of 1.27 beat Enhabit's score of 0.52 indicating that Enhabit is being referred to more favorably in the news media.
AdaptHealth has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Enhabit has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.
82.7% of AdaptHealth shares are owned by institutional investors. 4.4% of AdaptHealth shares are owned by insiders. Comparatively, 1.9% of Enhabit shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Enhabit has a net margin of -7.95% compared to Enhabit's net margin of -21.45%. Enhabit's return on equity of 8.47% beat AdaptHealth's return on equity.
Summary
AdaptHealth beats Enhabit on 12 of the 18 factors compared between the two stocks.
Get Enhabit News Delivered to You Automatically
Sign up to receive the latest news and ratings for EHAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EHAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
